

Our Ref: 114/2023
JANUARY 2023

Re: Your request made under the Freedom of Information Act 2000

Q1. How many patients were treated in the past 6 months (for any disease) with:

- Ruxolitinib 14
- Fedratinib 0

Q2. Does your trust treat myeloproliferative neoplasms? If not, which other trust do you refer these patients to?

YES

Q3. Please provide the total number of patients treated in the last 6 months for:

- Polycythaemia Vera (ICD10 code D45) 22
- Myelofibrosis (ICD10 code D47.4) 17
- Myelofibrosis (ICD10 code D47.4) patients aged 65 and older 11

Q4. Of the patients treated in the past 6 months with Ruxolitinib, how many patients had a diagnosis for:

- Polycythaemia Vera (ICD10 code D45)
- Myelofibrosis (ICD10 code D47.4)

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Q5. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years? 57

- Of the patients diagnosed with myelofibrosis in the past 3 years, how many were treated in the past 6 months with Hydroxycarbamide?
- Of the patients diagnosed with myelofibrosis in the past 3 years, how many were treated in the past 6 months with Interferon therapy?
- Of the patients diagnosed with myelofibrosis in the past 3 years, how many have received no active treatment in the past 6 months?

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Our Ref: 114/2023
JANUARY 2023